<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang Y</submitter><funding>Shanghai Municipal Science and Technology Commission</funding><funding>National Science Foundation of China</funding><funding>National Program on Key Basic Research Project (973 Program)</funding><pagination>45-56</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5360585</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17</volume><pubmed_abstract>Tumor relapse after radiotherapy is a significant challenge to oncologists, even after recent the advances in technologies. Here, we showed that cancer-associated fibroblasts (CAFs), a major component of cancer stromal cells, promoted irradiated cancer cell recovery and tumor relapse after radiotherapy. We provided evidence that CAFs-produced IGF1/2, CXCL12 and β-hydroxybutyrate were capable of inducing autophagy in cancer cells post-radiation and promoting cancer cell recovery from radiation-induced damage in vitro and in vivo in mice. These CAF-derived molecules increased the level of reactive oxygen species (ROS) post-radiation, which enhanced PP2A activity, repressing mTOR activation and increasing autophagy in cancer cells. Consistently, the IGF2 neutralizing antibody and the autophagy inhibitor 3-MA reduce the CAF-promoted tumor relapse in mice after radiotherapy. Taken together, our findings demonstrated that CAFs promoted irradiated cancer cell recovery and tumor regrowth post-radiation, suggesting that targeting the autophagy pathway in tumor cells may be a promising therapeutic strategy for radiotherapy sensitization.</pubmed_abstract><journal>EBioMedicine</journal><pubmed_title>Cancer-associated Fibroblasts Promote Irradiated Cancer Cell Recovery Through Autophagy.</pubmed_title><pmcid>PMC5360585</pmcid><funding_grant_id>11DZ2260200</funding_grant_id><funding_grant_id>2012CB910102</funding_grant_id><funding_grant_id>81572300</funding_grant_id><funding_grant_id>81372194</funding_grant_id><pubmed_authors>Wu J</pubmed_authors><pubmed_authors>Mi J</pubmed_authors><pubmed_authors>Wang B</pubmed_authors><pubmed_authors>Gan G</pubmed_authors><pubmed_authors>Zhu D</pubmed_authors><pubmed_authors>Ye M</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Cao Y</pubmed_authors><pubmed_authors>Han H</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Zhao J</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cancer-associated Fibroblasts Promote Irradiated Cancer Cell Recovery Through Autophagy.</name><description>Tumor relapse after radiotherapy is a significant challenge to oncologists, even after recent the advances in technologies. Here, we showed that cancer-associated fibroblasts (CAFs), a major component of cancer stromal cells, promoted irradiated cancer cell recovery and tumor relapse after radiotherapy. We provided evidence that CAFs-produced IGF1/2, CXCL12 and β-hydroxybutyrate were capable of inducing autophagy in cancer cells post-radiation and promoting cancer cell recovery from radiation-induced damage in vitro and in vivo in mice. These CAF-derived molecules increased the level of reactive oxygen species (ROS) post-radiation, which enhanced PP2A activity, repressing mTOR activation and increasing autophagy in cancer cells. Consistently, the IGF2 neutralizing antibody and the autophagy inhibitor 3-MA reduce the CAF-promoted tumor relapse in mice after radiotherapy. Taken together, our findings demonstrated that CAFs promoted irradiated cancer cell recovery and tumor regrowth post-radiation, suggesting that targeting the autophagy pathway in tumor cells may be a promising therapeutic strategy for radiotherapy sensitization.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Mar</publication><modification>2024-11-19T22:14:47.222Z</modification><creation>2019-03-27T02:39:14Z</creation></dates><accession>S-EPMC5360585</accession><cross_references><pubmed>28258923</pubmed><doi>10.1016/j.ebiom.2017.02.019</doi></cross_references></HashMap>